Calciprotein particle (CPP)

Calciprotein particles (CPPs) are colloidal complexes formed in extracellular fluids, primarily consisting of calcium phosphate minerals stabilized by fetuin-A and other plasma proteins, acting as a rapid mineral buffering system to prevent uncontrolled precipitation of hydroxyapatite crystals despite supersaturated calcium and phosphate levels. They exist as smaller precursors called calciprotein monomers (CPM), primary CPP (CPP1; amorphous, spherical ~50-100 nm), and secondary CPP (CPP2; crystalline, ellipsoid 100-300 nm), with high turnover kinetics cleared mainly by liver sinusoidal endothelial cells (for CPP1) and macrophages in liver/spleen (for CPP2). In physiology, CPPs inhibit ectopic calcification by chaperoning nascent mineral clusters, akin to a kinetic barrier against crystallization in sites like bone remodeling or the intestine. Pathologically, elevated CPPs in chronic kidney disease (CKD) associate with vascular calcification, endothelial dysfunction, inflammation, arterial stiffening, and cardiovascular disease through mechanisms like TLR4 activation, cytokine release (TNFα, IL-1β), and direct effects on vascular smooth muscle cells. While not a direct therapeutic target like a receptor or enzyme, CPP levels are modulated by interventions such as phosphate binders or bisphosphonates to mitigate these risks.

Other names

calciprotein monomers (CPM)primary calciprotein particles (CPP-I or CPP1)secondary calciprotein particles (CPP-II or CPP2)fetuin-A mineral complexes

Bisphosphonates reduce CPM aggregation and stall amorphous-to-crystalline phase shift; phosphate binders decrease CPP numbers